IMARA Inc. (IMRA)

$4.7

+0.16 (+3.52%)
Rating:
Recommendation:
-
Symbol IMRA
Price $4.7
Beta 1.050
Volume Avg. 0.11M
Market Cap 123.550M
Shares () -
52 Week Range 0.974-5.261
1y Target Est -
DCF Unlevered IMRA DCF ->
DCF Levered IMRA LDCF ->
ROE -64.98% Strong Sell
ROA -76.16% Strong Sell
Operating Margin -
Debt / Equity 3.17% Neutral
P/E -
P/B 2.16 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMRA news


Dr. Rahul D. Ballal Ph.D.
Healthcare
Biotechnology
NASDAQ Global Select

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.